{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T10:57:55Z","timestamp":1770980275798,"version":"3.50.1"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Behavioural Brain Research"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1016\/j.bbr.2016.04.033","type":"journal-article","created":{"date-parts":[[2016,4,29]],"date-time":"2016-04-29T15:52:19Z","timestamp":1461945139000},"page":"205-210","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["The norepinephrine reuptake inhibitor reboxetine is more potent in treating murine narcoleptic episodes than the serotonin reuptake inhibitor escitalopram"],"prefix":"10.1016","volume":"308","author":[{"given":"Christian","family":"Schmidt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith","family":"Leibiger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Fendt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbr.2016.04.033_bib0005","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0092-8674(00)80949-6","article-title":"Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior","volume":"92","author":"Sakurai","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.bbr.2016.04.033_bib0010","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1073\/pnas.95.1.322","article-title":"The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity","volume":"95","author":"de Lecea","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbr.2016.04.033_bib0015","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S0896-6273(00)00058-1","article-title":"Reduced number of hypocretin neurons in human narcolepsy","volume":"27","author":"Thannickal","year":"2000","journal-title":"Neuron"},{"key":"10.1016\/j.bbr.2016.04.033_bib0020","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0092-8674(00)81965-0","article-title":"The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene","volume":"98","author":"Lin","year":"1999","journal-title":"Cell"},{"key":"10.1016\/j.bbr.2016.04.033_bib0025","doi-asserted-by":"crossref","first-page":"7273","DOI":"10.1523\/JNEUROSCI.21-18-07273.2001","article-title":"Hypocretin-2-saporin lesions of the lateral hypothalamus produce narcoleptic-like sleep behavior in the rat","volume":"21","author":"Gerashchenko","year":"2001","journal-title":"J. Neurosci."},{"key":"10.1016\/j.bbr.2016.04.033_bib0030","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S0092-8674(00)81973-X","article-title":"Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation","volume":"98","author":"Chemelli","year":"1999","journal-title":"Cell"},{"key":"10.1016\/j.bbr.2016.04.033_bib0035","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1056\/NEJMra1500587","article-title":"Narcolepsy","volume":"373","author":"Scammell","year":"2015","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.bbr.2016.04.033_bib0040","first-page":"9","article-title":"Narcolepsy: pathophysiology and pharmacology","volume":"68","author":"Nishino","year":"2007","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.bbr.2016.04.033_bib0045","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s13311-012-0150-9","article-title":"A practical guide to the therapy of narcolepsy and hypersomnia syndromes","volume":"9","author":"Mignot","year":"2012","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.bbr.2016.04.033_bib0050","first-page":"77","article-title":"Validation of a cataplexy questionnaire in 983 sleep-disorders patients","volume":"22","author":"Anic-Labat","year":"1999","journal-title":"Sleep"},{"key":"10.1016\/j.bbr.2016.04.033_bib0055","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1517\/14728210903559852","article-title":"Emerging treatments for narcolepsy and its related disorders","volume":"15","author":"Nishino","year":"2010","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"10.1016\/j.bbr.2016.04.033_bib0060","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S0306-4522(98)00600-9","article-title":"Locus coeruleus neurons: cessation of activity during cataplexy","volume":"91","author":"Wu","year":"1999","journal-title":"Neuroscience"},{"key":"10.1016\/j.bbr.2016.04.033_bib0065","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1113\/jphysiol.2003.052134","article-title":"Activity of dorsal raphe cells across the sleep-waking cycle and during cataplexy in narcoleptic dogs","volume":"554","author":"Wu","year":"2004","journal-title":"J. Physiol."},{"key":"10.1016\/j.bbr.2016.04.033_bib0070","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/BF02244337","article-title":"Canine cataplexy is preferentially controlled by adrenergic mechanisms: evidence using monoamine selective uptake inhibitors and release enhancers","volume":"113","author":"Mignot","year":"1993","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.bbr.2016.04.033_bib0075","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1093\/sleep\/16.8.706","article-title":"Desmethyl metabolites of serotonergic uptake inhibitors are more potent for suppressing canine cataplexy than their parent compounds","volume":"16","author":"Nishino","year":"1993","journal-title":"Sleep"},{"key":"10.1016\/j.bbr.2016.04.033_bib0080","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1093\/sleep\/12.3.254","article-title":"Exacerbation of human cataplexy by prazosin","volume":"12","author":"Aldrich","year":"1989","journal-title":"Sleep"},{"key":"10.1016\/j.bbr.2016.04.033_bib0085","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1016\/j.cub.2013.07.014","article-title":"A noradrenergic mechanism functions to couple motor behavior with arousal state","volume":"23","author":"Burgess","year":"2013","journal-title":"Curr. Biol."},{"key":"10.1016\/j.bbr.2016.04.033_bib0090","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.neubiorev.2005.03.008","article-title":"Assessing substrates underlying the behavioral effects of antidepressants using the modified rat forced swimming test","volume":"29","author":"Cryan","year":"2005","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.bbr.2016.04.033_bib0095","first-page":"493","article-title":"Involvement of the monoaminergic system in the antidepressant-like activity of chromium chloride in the forced swim test","volume":"64","author":"Piotrowska","year":"2013","journal-title":"J. Physiol. Pharmacol."},{"key":"10.1016\/j.bbr.2016.04.033_bib0100","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s002130000630","article-title":"Modulation of MK-801-induced behaviour by noradrenergic agents in mice","volume":"154","author":"Harkin","year":"2001","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.bbr.2016.04.033_bib0105","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.pnpbp.2013.01.014","article-title":"The activation of alpha(1)-adrenoceptors is implicated in the antidepressant-like effect of creatine in the tail suspension test","volume":"44","author":"Cunha","year":"2013","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.bbr.2016.04.033_bib0110","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.neuint.2013.02.024","article-title":"GPR39 up-regulation after selective antidepressants","volume":"62","author":"Mlyniec","year":"2013","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.bbr.2016.04.033_bib0115","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.bbr.2015.03.053","article-title":"Study of antidepressant drugs in GPR39 (zinc receptor\u2212\/\u2212) knockout mice, showing no effect of conventional antidepressants, but effectiveness of NMDA antagonists","volume":"287","author":"Mlyniec","year":"2015","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.bbr.2016.04.033_bib0120","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1007\/s10519-013-9634-6","article-title":"Behavioral analysis of narcoleptic episodes in orexin-deficient mice","volume":"44","author":"Leibiger","year":"2014","journal-title":"Behav. Genet."},{"key":"10.1016\/j.bbr.2016.04.033_bib0125","doi-asserted-by":"crossref","first-page":"111","DOI":"10.5665\/sleep\/32.1.111","article-title":"A consensus definition of cataplexy in mouse models of narcolepsy","volume":"32","author":"Scammell","year":"2009","journal-title":"Sleep"},{"key":"10.1016\/j.bbr.2016.04.033_bib0130","series-title":"Caract\u00e9risation du ph\u00e9noytpe narcoleptique et cataplectique des souris d\u00e9ficientes pour le syst\u00e9me orexinergique. Master Thesis","author":"Mang","year":"2010"},{"key":"10.1016\/j.bbr.2016.04.033_bib0135","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.5665\/sleep.2232","article-title":"The dual orexin receptor antagonist almorexant induces sleep and decreases orexin-induced locomotion by blocking orexin 2 receptors","volume":"35","author":"Mang","year":"2012","journal-title":"Sleep"},{"key":"10.1016\/j.bbr.2016.04.033_bib0140","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.nbd.2007.12.003","article-title":"An inverse agonist of the histamine H-3 receptor improves wakefulness in narcolepsy: studies in orexin\u2212\/\u2212 mice and patients","volume":"30","author":"Lin","year":"2008","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.bbr.2016.04.033_bib0145","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1002\/ana.10444","article-title":"The neurobiology, diagnosis, and treatment of narcolepsy","volume":"53","author":"Scammell","year":"2003","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.bbr.2016.04.033_bib0150","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/sj.bjp.0707253","article-title":"Tricyclic antidepressant pharmacology and therapeutic drug interactions updated","volume":"151","author":"Gillman","year":"2007","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bbr.2016.04.033_bib0155","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1093\/sleep\/32.2.175","article-title":"Decreased CSF histamine in narcolepsy with and without low CSF hypocretin-1 in comparison to healthy controls","volume":"32","author":"Nishino","year":"2009","journal-title":"Sleep"},{"key":"10.1016\/j.bbr.2016.04.033_bib0160","doi-asserted-by":"crossref","first-page":"205","DOI":"10.2165\/00139709-200524030-00013","article-title":"Tricyclic antidepressant poisoning: cardiovascular toxicity","volume":"24","author":"Thanacoody","year":"2005","journal-title":"Toxicol. Rev."},{"key":"10.1016\/j.bbr.2016.04.033_bib0165","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0006-3223(01)01145-3","article-title":"Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine","volume":"50","author":"Owens","year":"2001","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.bbr.2016.04.033_bib0170","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1002\/(SICI)1099-1077(199802)13:1+<S13::AID-HUP979>3.0.CO;2-6","article-title":"Rationale for the development of noradrenaline reuptake inhibitors","volume":"13","author":"Brunello","year":"1998","journal-title":"Hum. Psychopharm. Clin."},{"key":"10.1016\/j.bbr.2016.04.033_bib0175","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/S0140-6736(09)60046-5","article-title":"Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis","volume":"373","author":"Cipriani","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.bbr.2016.04.033_bib0180","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1586\/14737175.8.4.537","article-title":"Escitalopram for the treatment of major depression and anxiety disorders","volume":"8","author":"H\u00f6schl","year":"2008","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.bbr.2016.04.033_bib0185","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/YIC.0b013e32835a5d2e","article-title":"Newer antidepressants and panic disorder: a meta-analysis","volume":"28","author":"Andrisano","year":"2013","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.bbr.2016.04.033_bib0190","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3109\/08039488.2014.972975","article-title":"A systematic review of reboxetine for treating patients with attention deficit hyperactivity disorder","volume":"69","author":"Ghanizadeh","year":"2015","journal-title":"Nord. J. Psychiatry"},{"key":"10.1016\/j.bbr.2016.04.033_bib0195","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1093\/sleep\/24.3.282","article-title":"Stimulant and anticataplectic effects of reboxetine in patients with narcolepsy: a pilot study","volume":"24","author":"Larrosa","year":"2001","journal-title":"Sleep"},{"key":"10.1016\/j.bbr.2016.04.033_bib0200","first-page":"174","article-title":"Cataplexy treated with escitalopram\u2014clinical experience","volume":"27","author":"Sonka","year":"2006","journal-title":"Neuroendocrinol. Lett."},{"key":"10.1016\/j.bbr.2016.04.033_bib0205","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1136\/vr.142.2.31","article-title":"Breeding history of the Stanford colony of narcoleptic dogs","volume":"142","author":"Cederberg","year":"1998","journal-title":"Vet. Rec."},{"key":"10.1016\/j.bbr.2016.04.033_bib0210","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1093\/sleep\/30.11.1417","article-title":"Running promotes wakefulness and increases cataplexy in orexin knockout mice","volume":"30","author":"Espana","year":"2007","journal-title":"Sleep"},{"key":"10.1016\/j.bbr.2016.04.033_bib0215","doi-asserted-by":"crossref","first-page":"9734","DOI":"10.1523\/JNEUROSCI.5632-12.2013","article-title":"Amygdala lesions reduce cataplexy in orexin knock-out mice","volume":"33","author":"Burgess","year":"2013","journal-title":"J. Neurosci."},{"key":"10.1016\/j.bbr.2016.04.033_bib0220","doi-asserted-by":"crossref","first-page":"4527","DOI":"10.1007\/s00213-014-3595-1","article-title":"The interaction of escitalopram and R-citalopram at the human serotonin transporter investigated in the mouse","volume":"231","author":"Jacobsen","year":"2014","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.bbr.2016.04.033_bib0225","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1016\/S0924-977X(97)00417-3","article-title":"Review of the pharmacokinetics and metabolism of reboxetine, a selective noradrenaline reuptake inhibitor","volume":"7","author":"Dostert","year":"1997","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.bbr.2016.04.033_bib0230","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/S0006-3223(99)00291-7","article-title":"Reboxetine: a pharmacologically potent, selective, and specific norepinephrine reuptake inhibitor","volume":"47","author":"Wong","year":"2000","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.bbr.2016.04.033_bib0235","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s00213-002-1364-z","article-title":"Escitalopram the S-(+)-enantiomer of citalopram, is a selective serotonin reuptake inhibitor with potent effects in animal models predictive of antidepressant and anxiolytic activities","volume":"167","author":"Sanchez","year":"2003","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.bbr.2016.04.033_bib0240","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1527-3458.2004.tb00002.x","article-title":"The selective norepinephrine reuptake inhibitor antidepressant reboxetine: pharmacological and clinical profile","volume":"10","author":"Haj\u00f3s","year":"2004","journal-title":"CNS Drug Rev."},{"key":"10.1016\/j.bbr.2016.04.033_bib0245","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1038\/sj.npp.1300989","article-title":"Disruption of prepulse inhibition after stimulation of central but not peripheral [alpha]-1 adrenergic receptors","volume":"31","author":"Alsene","year":"2006","journal-title":"Neuropsychopharmacology"}],"container-title":["Behavioural Brain Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166432816302352?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166432816302352?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T13:08:52Z","timestamp":1759064932000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166432816302352"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":49,"alternative-id":["S0166432816302352"],"URL":"https:\/\/doi.org\/10.1016\/j.bbr.2016.04.033","relation":{},"ISSN":["0166-4328"],"issn-type":[{"value":"0166-4328","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The norepinephrine reuptake inhibitor reboxetine is more potent in treating murine narcoleptic episodes than the serotonin reuptake inhibitor escitalopram","name":"articletitle","label":"Article Title"},{"value":"Behavioural Brain Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbr.2016.04.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}